Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China

The license agreement provides Nuance Pharma exclusive rights to develop and commercialize AeroFact™ for treatment of Respiratory Distress Syndrome (RDS) in all of Greater China.

Aerogen Pharma will receive upfront payment of $20 million and $10 million equity in Nuance Pharma, as well as potential development, regulatory, and commercial milestone payments totalling $182.5 million, plus escalating tiered low double-digit royalties on net sales within the territory. 

Aerogen Pharma and Lyomark Pharma partner to develop inhaled surfactant, begin a Phase 2 clinical trial an alliance to improve lung disease treatment in premature birth

Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Lyomark Pharma, an established provider of high quality medicines for the hospital market, are joining forces to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.